Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
In vitro
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
In vitro
Emergency use authorization Experimental Antiviral Jan/23/2023
T cells
In vitro
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jan/18/2023
Remdesivir
In vitro
Approved by FDA Experimental Antiviral Jan/18/2023
Mesenchymal stem cells
In vitro
Potential treatment - clinical evidence Experimental Other treatment Oct/17/2022
Anti-spike nanobody-IFN-β conjugated exosomes
In vitro
Potential treatment - pre-clinical evidence Experimental Antiviral Sep/26/2022
IMAT-MSCs
In vitro
Potential treatment - pre-clinical evidence Experimental Other treatment Sep/23/2022
Exosomal vaccine
In vitro
Potential treatment - pre-clinical evidence Experimental Vaccine Jul/29/2022
Sotrovimab
In vitro
Emergency use authorization Experimental Antiviral Jul/14/2022
Nirmatrelvir
In vitro
Emergency use authorization Experimental Antiviral Jun/23/2022
Bamlanivimab
In vitro
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
In vitro
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
S309
In vitro
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
Ad26.COV2.S
In vitro
Emergency use authorization Experimental Vaccine Jun/22/2022
BNT162b2
In vitro
Approved by FDA Experimental Vaccine Jun/22/2022
mRNA-1273
In vitro
Emergency use authorization Experimental Vaccine Jun/22/2022
Cilgavimab
In vitro
Emergency use authorization Experimental Antiviral Jun/18/2022
Tixagevimab
In vitro
Emergency use authorization Experimental Antiviral Jun/18/2022
Bebtelovimab
In vitro
Emergency use authorization Experimental Antiviral Jun/18/2022
REGEN-COV
In vitro
Emergency use authorization Experimental Antiviral Jun/03/2022